Conmed (CNMD) Tops Q3 EPS by 3c; offers guidance

Conmed (NYSE: CNMD) reported Q3 EPS of $1.08, $0.03 better than the analyst estimate of $1.05. Revenue for the quarter came in at $337.9 million versus the consensus estimate of $334.71 million.

GUIDANCE:

Conmed sees FY2025 EPS of $4.48-$4.53, versus the consensus of $4.47. Conmed sees FY2025 revenue of $1.365-1.372 billion, versus the consensus of $1.367 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• Pentagon-Backed Oil Company Is Set to Vie for Chevron's Crown in Venezuela - WSJ
• Krait Critical Minerals closes $1.22M first tranche of placement